| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic Science Investigation |
1 Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 2 Biological Engineering Division, Massachusetts Institute of Technology, Cambridge, Massachusetts
Correspondence: For correspondence or reprints contact: K. Dane Wittrup, PhD, Department of Chemical Engineering and Biological Engineering Division, Massachusetts Institute of Technology, Building E19-551, 77 Massachusetts Ave., Cambridge, MA 02139. E-mail: wittrup{at}mit.edu
Targeting tumors with antibody-based therapeutics is a complex task presenting multiple kinetic barriers. Antibody internalization and clearance inhibit uptake both in solid tumors, limited by tumor vascular permeability, and in micrometastases, limited by diffusion. Methods: A modeling exercise is used to introduce 2 simple criteria that must be less than unity for saturation of both tumors and micrometastases. The clearance modulus and the Thiele modulus are ratios of the plasma clearance rate and antibody catabolism, respectively, to the tumor tissue penetration rate. Results: Even low rates of antigen internalization from constitutive membrane turnover can significantly retard antibody penetration. Rapid clearance of single-chain variable fragments also hinders uptake, often more than counterbalancing their more rapid extravasation and diffusion. Conclusion: The model illustrates that with the large resistance from the tumor capillary, antibodies may be more suitable for targeting micrometastases than vascularized tumors.
Key Words: molecular imaging • monoclonal antibodies • radionuclide therapy • biodistribution • penetration • pharmacokinetics
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  B. Verma, F. A. Neethling, S. Caseltine, G. Fabrizio, S. Largo, J. A. Duty, P. Tabaczewski, and J. A. Weidanz TCR Mimic Monoclonal Antibody Targets a Specific Peptide/HLA Class I Complex and Significantly Impedes Tumor Growth In Vivo Using Breast Cancer Models J. Immunol., February 15, 2010; 184(4): 2156 - 2165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Santoro, S. Boutaleb, V. Garambois, C. Bascoul-Mollevi, V. Boudousq, P.-O. Kotzki, M. Pelegrin, I. Navarro-Teulon, A. Pelegrin, and J.-P. Pouget Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis J. Nucl. Med., December 1, 2009; 50(12): 2033 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Schmidt and K. D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol. Cancer Ther., October 1, 2009; 8(10): 2861 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tolmachev, M. Friedman, M. Sandstrom, T. L.J. Eriksson, D. Rosik, M. Hodik, S. Stahl, F. Y. Frejd, and A. Orlova Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry J. Nucl. Med., February 1, 2009; 50(2): 274 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Ackerman, D. Pawlowski, and K. D. Wittrup Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther., July 1, 2008; 7(7): 2233 - 2240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Thurber and K. D. Wittrup Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids Cancer Res., May 1, 2008; 68(9): 3334 - 3341. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
